NASDAQ:ATRS Antares Pharma Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Antares Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $5.59 0.00 (0.00%) (As of 06/29/2022) Add Compare Share Today's Range$5.59▼$5.5950-Day Range$5.56▼$5.5952-Week Range$3.11▼$5.60Volume435 shsAverage Volume3.29 million shsMarket Capitalization$955.06 millionP/E Ratio23.29Dividend YieldN/APrice Target$5.60 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Antares Pharma MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside0.2% Upside$5.60 Price TargetShort InterestN/ADividend StrengthN/ASustainability-2.46Upright™ Environmental ScoreNews Sentiment0.30Based on 2 Articles This WeekInsider TradingN/AProj. Earnings Growth175.00%From $0.08 to $0.22 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.1.96 out of 5 starsMedical Sector550th out of 1,426 stocksSurgical & Medical Instruments Industry68th out of 136 stocks 2.0 Analyst's Opinion Consensus RatingAntares Pharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.60, Antares Pharma has a forecasted upside of 0.2% from its current price of $5.59.Amount of Analyst CoverageAntares Pharma has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 0.0 Short Interest Short InterestThere is no current short interest data available for ATRS. Previous Next 0.0 Dividend Strength Dividend YieldAntares Pharma does not currently pay a dividend.Dividend GrowthAntares Pharma does not have a long track record of dividend growth. Previous Next 2.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAntares Pharma has received a 46.48% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Sumatriptan", "Epinephrine", and "Desmopressin" products. See details.Environmental SustainabilityThe Environmental Impact score for Antares Pharma is -2.46. Previous Next 1.8 News and Social Media Coverage News SentimentAntares Pharma has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Antares Pharma this week, compared to 0 articles on an average week.MarketBeat FollowsOnly 1 people have added Antares Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Antares Pharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.90% of the stock of Antares Pharma is held by insiders.Percentage Held by Institutions50.41% of the stock of Antares Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Antares Pharma are expected to grow by 175.00% in the coming year, from $0.08 to $0.22 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Antares Pharma is 23.29, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 89.99.Price to Earnings Ratio vs. SectorThe P/E ratio of Antares Pharma is 23.29, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 81.02.Price to Book Value per Share RatioAntares Pharma has a P/B Ratio of 5.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ATRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Antares Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address About Antares Pharma (NASDAQ:ATRS) StockAntares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and commercializes novel therapeutic products using its drug delivery systems. The company's injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate. Its injection products also comprise generic Epinephrine Injection USP products indicated for emergency treatment of severe allergic reactions, including anaphylaxis in adults and certain pediatric patients; Sumatriptan Injection USP indicated for the acute treatment of migraine headaches and cluster headache in adults; and Makena subcutaneous auto-injector drug-device combination product indicated to reduce the risk of preterm birth in women, as well as Teriparatide injection used for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and glucocorticoid induced osteoporosis in men and women. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; QuickShot auto-injectors; TLANDO to treat deficiency or absence of endogenous testosterone in adult males; and drug/device products for urologic oncology, immunology, and endocrinology. The company has strategic alliances and partnerships with Pfizer Inc., Idorsia Pharmaceuticals Ltd, Teva Pharmaceutical Industries, Ltd, and AMAG. Antares Pharma, Inc. was incorporated in 1979 and is headquartered in Ewing, New Jersey.Read More ATRS Stock News HeadlinesJuly 1, 2022 | americanbankingnews.comAntares Pharma, Inc. (NASDAQ:ATRS) Receives $5.60 Average Target Price from BrokeragesJune 11, 2022 | americanbankingnews.comStockNews.com Begins Coverage on Antares Pharma (NASDAQ:ATRS)June 8, 2022 | msn.comLooking Into Antares Pharma's Return On Invested CapitalMay 19, 2022 | seekingalpha.comHalozyme: Antares Pharma Bolsters Growth ProspectsMay 6, 2022 | finance.yahoo.comMiMedx Group and Inozyme Stock See Action From Activist InvestorsApril 26, 2022 | finance.yahoo.comHALOZYME COMMENCES TENDER OFFER FOR ALL OUTSTANDING SHARES OF COMMON STOCK OF ANTARES PHARMAApril 14, 2022 | benzinga.comLooking Into Antares Pharma Inc's Recent Short InterestApril 14, 2022 | finance.yahoo.comAntares Pharma (ATRS) Moves 49.2% Higher: Will This Strength Last?April 13, 2022 | finance.yahoo.comAntares Pharma to be acquired by Halozyme in $960M dealApril 13, 2022 | investorplace.comWhy Is Antares Pharma (ATRS) Stock Up Today?April 13, 2022 | morningstar.comAntares Pharma stock rockets after Halozyme buyout deal for a near-50% premiumApril 13, 2022 | fool.comWhy Antares Pharma Stock Is Bolting Higher TodayMarch 29, 2022 | msn.comThe Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For AkebiaMarch 29, 2022 | seekingalpha.comAntares wins full FDA approval for testosterone replacement therapyMarch 29, 2022 | finance.yahoo.comAntares Pharma Announces FDA Approval Of TLANDO™, an Oral Treatment for Testosterone Replacement TherapyMarch 8, 2022 | benzinga.comAntares Pharma's Return On Capital Employed OverviewMarch 8, 2022 | seekingalpha.comAntares Pharma (ATRS) Investor Presentation - SlideshowMarch 3, 2022 | apnews.comAntares Pharma: Q4 Earnings SnapshotMarch 3, 2022 | finance.yahoo.comAntares Pharma Reports Fourth Quarter and Full-Year 2021 Financial and Operating ResultsMarch 3, 2022 | finance.yahoo.comAntares Pharma (ATRS) Surpasses Q4 Earnings and Revenue EstimatesFebruary 28, 2022 | finance.yahoo.comSmileDirectClub (SDC) Reports Q4 Loss, Lags Revenue EstimatesFebruary 28, 2022 | finance.yahoo.comAntares Pharma to Present at the Cowen 42nd Annual Healthcare ConferenceFebruary 18, 2022 | finance.yahoo.comAntares Pharma (NASDAQ:ATRS) Could Easily Take On More DebtFebruary 15, 2022 | finance.yahoo.comHenry Schein (HSIC) Q4 Earnings and Revenues Beat EstimatesJanuary 13, 2022 | nasdaq.comHere's Why I Think Antares Pharma (NASDAQ:ATRS) Might Deserve Your Attention TodaySee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Supplies SectorMedical Current SymbolNASDAQ:ATRS CUSIP03664210 CIK1016169 Webwww.antarespharma.com Phone(609) 359-3020Fax302-655-5049Employees201Year FoundedN/ACompany Calendar Last Earnings5/10/2022Today7/06/2022Next Earnings (Estimated)8/04/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$5.60 High Stock Price Forecast$5.60 Low Stock Price Forecast$5.60 Forecasted Upside/Downside+0.2%Consensus RatingHold Rating Score (0-4)2 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)$0.24 Trailing P/E Ratio23.29 Forward P/E Ratio69.88 P/E GrowthN/ANet Income$46.29 million Net Margins21.90% Pretax Margin29.84% Return on Equity7.43% Return on Assets4.92% Debt Debt-to-Equity Ratio0.10 Current Ratio3.08 Quick Ratio2.87 Sales & Book Value Annual Sales$183.98 million Price / Sales5.19 Cash Flow$0.13 per share Price / Cash Flow43.89 Book Value$1.03 per share Price / Book5.43Miscellaneous Outstanding Shares170,852,000Free Float160,772,000Market Cap$955.06 million OptionableOptionable Beta1.15 Antares Pharma Frequently Asked Questions Should I buy or sell Antares Pharma stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Antares Pharma in the last year. There are currently 5 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Antares Pharma stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ATRS, but not buy additional shares or sell existing shares. View analyst ratings for Antares Pharma or view top-rated stocks. What is Antares Pharma's stock price forecast for 2022? 5 brokerages have issued 1-year price objectives for Antares Pharma's shares. Their ATRS stock forecasts range from $5.60 to $5.60. On average, they expect Antares Pharma's stock price to reach $5.60 in the next twelve months. This suggests a possible upside of 0.2% from the stock's current price. View analysts' price targets for Antares Pharma or view top-rated stocks among Wall Street analysts. How has Antares Pharma's stock price performed in 2022? Antares Pharma's stock was trading at $3.57 at the start of the year. Since then, ATRS stock has increased by 56.6% and is now trading at $5.59. View the best growth stocks for 2022 here. When is Antares Pharma's next earnings date? Antares Pharma is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Antares Pharma. How were Antares Pharma's earnings last quarter? Antares Pharma, Inc. (NASDAQ:ATRS) issued its quarterly earnings results on Tuesday, May, 10th. The specialty pharmaceutical company reported ($0.01) EPS for the quarter. The specialty pharmaceutical company had revenue of $41.56 million for the quarter, compared to analyst estimates of $44.01 million. Antares Pharma had a net margin of 21.90% and a trailing twelve-month return on equity of 7.43%. View Antares Pharma's earnings history. Who are Antares Pharma's key executives? Antares Pharma's management team includes the following people: Mr. Robert F. Apple, CEO, Pres & Director (Age 56, Pay $1M)Mr. Fred M. Powell CPA, Exec. VP & CFO (Age 61, Pay $636.39k)Mr. Peter J. Graham Esq., Exec. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 55, Pay $634.48k)Mr. Patrick Madsen, Sr. VP of OperationsMr. Keith Muckenhirn, Principal Accounting Officer, VP of Fin. & Corp. Controller (Age 59)Ms. Tram Bui, VP of Corp. Communications & Investor RelationsMr. Edward Tykot, Sr. VP of Corp. Bus. Devel.Mr. Claude E. Richardson, Sr. VP of HRDr. Peter Sadowski, Sr. VP of Technology Portfolio & Intellectual Property (Age 74)Dr. Jonathan S. Jaffe, Interim EVP, Pharmaceutical R&D and Chief Medical Officer What is Paul K. Wotton's approval rating as Antares Pharma's CEO? 5 employees have rated Antares Pharma CEO Paul K. Wotton on Glassdoor.com. Paul K. Wotton has an approval rating of 18% among Antares Pharma's employees. This puts Paul K. Wotton in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are some of Antares Pharma's key competitors? Some companies that are related to Antares Pharma include West Pharmaceutical Services (WST), Align Technology (ALGN), Cooper Companies (COO), DENTSPLY SIRONA (XRAY), QuidelOrtho (QDEL), ICU Medical (ICUI), STAAR Surgical (STAA), Haemonetics (HAE), Merit Medical Systems (MMSI), Neogen (NEOG), Meridian Bioscience (VIVO), Atrion (ATRI), Cerus (CERS), Anika Therapeutics (ANIK) and Utah Medical Products (UTMD). View all of ATRS's competitors. What other stocks do shareholders of Antares Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Antares Pharma investors own include Ballard Power Systems (BLDP), Advanced Micro Devices (AMD), Novavax (NVAX), (CGC), NVIDIA (NVDA), Conatus Pharmaceuticals (CNAT), Micron Technology (MU), Prospect Capital (PSEC), Gilead Sciences (GILD) and Sorrento Therapeutics (SRNE). What is Antares Pharma's stock symbol? Antares Pharma trades on the NASDAQ under the ticker symbol "ATRS." How do I buy shares of Antares Pharma? Shares of ATRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Antares Pharma's stock price today? One share of ATRS stock can currently be purchased for approximately $5.59. How much money does Antares Pharma make? Antares Pharma (NASDAQ:ATRS) has a market capitalization of $955.06 million and generates $183.98 million in revenue each year. The specialty pharmaceutical company earns $46.29 million in net income (profit) each year or $0.24 on an earnings per share basis. How many employees does Antares Pharma have? Antares Pharma employs 201 workers across the globe. How can I contact Antares Pharma? Antares Pharma's mailing address is 100 PRINCETON SOUTH SUITE 300, EWING NJ, 08628. The official website for Antares Pharma is www.antarespharma.com. The specialty pharmaceutical company can be reached via phone at (609) 359-3020, via email at jhowarth@antarespharma.com, or via fax at 302-655-5049. This page (NASDAQ:ATRS) was last updated on 7/6/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
